Analysis of mutations in the genes pink1 and parkin in Colombian patients with Parkinson's disease

Análisis de mutaciones en los genes PINK1 Y PARKIN en pacientes colombianos con enfermedad de Parkinson

Published 2014-07-01

Open | Download
PDF (Spanish) FLIP HTML (Spanish)
Issue
Vol. 12 No. 21 (2014)
Section
Artículo Original Producto de Investigación
How to Cite
Infante Molina, C. A., Mora Forero, L. M., Ortega Rojas, J. C., Arboleda-Bustos, C. E., Fernández, W., Arboleda, H., & Arboleda, G. (2014). Analysis of mutations in the genes pink1 and parkin in Colombian patients with Parkinson’s disease. NOVA, 12(21). https://doi.org/10.22490/24629448.993
DOI

https://doi.org/10.22490/24629448.993
Dimensions
PlumX
license

Licencia Creative Commons

NOVA by http://www.unicolmayor.edu.co/publicaciones/index.php/nova is distributed under a license creative commons non comertial-atribution-withoutderive 4.0 international.

Furthermore, the authors keep their property intellectual rights over the articles.

 

Carolina Andrea Infante Molina
    Laura Marlen Mora Forero
      Jenny C. Ortega Rojas
        Carlos E. Arboleda-Bustos
          William Fernández
            Humberto Arboleda
              Gonzalo Arboleda
                Show authors biography
                Parkinson's disease is a complex neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons of the substance nigra pars compacta. It has been determined that factors both environmental and genetic contribute to its development. Mutations in the genes PINK1 and PARKIN have been associated with the early onset of disease and family history. The goal of this study was to identify mutations in the PINK1 genes (exons 4 and 6) and PARKIN (exons 2 and 7) in 22 Colombian patients with Parkinson's disease of early onset and/or family history, by PCR amplification and sequencing. The sequences were compared with the reference consensus sequence. A homozygous change mutation was detected in the reading frame (frame shift) c.155dela in exon 2 of the PARKIN gene in a patient with early onset of the disease and family history. In addition, the presence of a polymorphism in intron 2 of the PARKIN gene was identified in seven patients, one of them in homozygous state. Mutations were not found in exons 4 and 6 of the gene PINK1. A homozygous mutation c.155dela in exon 2 of PARKIN was found in a female patient with Parkinson's disease early onset with family history. No changes to the gene PINK1 were found.

                Article visits 418 | PDF visits 168

                Downloads

                Download data is not yet available.
                1. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Ge-netic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat. 2010;31(7):763-780.
                2. Qayyum A. Etiology and Pathophysiology of Parkinson’s Di-sease. In: Rana AQ, ed: InTech; 2011.
                3. Fahn S, Jankovic J, Hallett M. Chapter 5 - Current concepts on the etiology and pathogenesis of Parkinson disease. Princi-ples and Practice of Movement Disorders 2° Edition ed. Edin-burgh: W.B. Saunders; 2011:93-118.
                4. Pradilla AG, Vesga AB, Leon-Sarmiento FE. [National neu-roepidemiological study in Colombia (EPINEURO)]. Rev Panam Salud Publica. 2003;14(2):104-111.
                5. Pankratz ND, Wojcieszek J, Foroud T. Parkinson Disease Overview. 2009.
                6. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous muta-tions in genes associated with parkinsonism. Lancet Neurol. 2007;6(7):652-662.
                7. Camargos ST, Dornas LO, Momeni P, Lees A, Hardy J, Single-ton A, et al. Familial Parkinsonism and early onset Parkinson’s disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations. Mov Disord. 2009;24(5):662-666.
                8. Scornaienchi V, Civitelli D, De Marco EV, Annesi G, Tarantino P, Rocca FE, et al. Mutation analysis of the PINK1 gene in Southern Italian patients with early- and late-onset parkinso-nism. Parkinsonism Relat Disord. 2012;18(5):651-653.
                9. Yonova-Doing E, Atadzhanov M, Quadri M, Kelly P, Shawa N, Musonda ST, et al. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson’s disea-se. Parkinsonism Relat Disord. 2012;18(5):567-571.
                10. Thomas B, Beal MF. Parkinsons disease. Hum Mol Genet. 2007;16 Spec No. 2:R183-194.
                11. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 2011;26 Suppl 1:S1-58.
                12. Fung HC, Chen CM, Hardy J, Singleton AB, Lee-Chen GJ, Wu YR. Analysis of the PINK1 gene in a cohort of patients with sporadic early-onset parkinsonism in Taiwan. Neurosci Lett. 2006;394(1):33-36.
                13. Cookson MR, Bandmann O. Parkinson’s disease: insights from pathways. Hum Mol Genet. 2010;19(R1):R21-27.
                14. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Mino-shima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25(3):302-305.
                15. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A. 2000;97(24):13354-13359.
                16. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, et al. PINK1 is selectively stabilized on impaired mitochon-dria to activate Parkin. PLoS Biol. 2010;8(1):e1000298.
                17. Douglas J. Diagnostic criteria for Parkinson disease. . Archives of Neurology. 1999; Vol 56(1): 33-39.
                18. Clarke CE. Parkinson’s disease. Bmj. 2007;335(7617):441-445.
                19. Jankovic J. Parkinsons disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.
                20. Sironi F, Primignani P, Zini M, Tunesi S, Ruffmann C, Ricca S, et al. Parkin analysis in early onset Parkinson’s disease. Par-kinsonism Relat Disord. 2008;14(4):326-333.
                21. Kitada T, Asakawa S, Hattori N, Matsumine H, Yama-mura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605-608.
                22. Periquet M, Latouche M, Lohmann E, Rawal N, De Michele G, Ricard S, et al. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain. 2003;126(Pt 6):1271-1278.
                23. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science. 2004;304(5674):1158-1160.
                24. Hall TA. BioEdit: a user-friendly biological sequence align-ment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 1999;41:95-98.
                25. Weckx S, Del-Favero J, Rademakers R, Claes L, Cruts M, De Jonghe P, et al. novoSNP, a novel computational tool for sequen-ce variation discovery. Genome Res. 2005;15(3):436-442.
                26. Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Mi-chele G, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Euro-pe. French Parkinson’s Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson’s Disease. Hum Mol Genet. 1999;8(4):567-574.
                27. Munoz E, Tolosa E, Pastor P, Marti MJ, Valldeoriola F, Cam-pdelacreu J, et al. Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism. J Neurol Neurosurg Psychiatry. 2002;73(5):582-584.
                28. Pineda-Trujillo N, Dulcey Cepeda A, Arias Pérez W, More-no Masmela S, Saldarriaga Henao A, Sepúlveda Falla D, et al. Una mutación en el gen PARK2 causa enfermedad de Parkinson juvenil en una extensa familia colombiana. Iatreia. 2009;22 (2):122-131.
                29. Oliveira SA, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, et al. Association study of Parkin gene poly-morphisms with idiopathic Parkinson disease. Arch Neurol. 2003;60(7):975-980.
                30. Solla P, Cannas A, Floris G, Murru MR, Corongiu D, Tranquilli S, et al. Parkin Exon Rearrangements and Sequence Variants in LRRK2 Mutations Carriers: Analysis on a Possible Modifier Effect on LRRK2 Penetrance. Parkinsons Dis. 2010;2010:537698.
                31. Hoenicka J, Vidal L, Morales B, Ampuero I, Jimenez-Jimenez FJ, Berciano J, et al. Molecular findings in familial Parkinson disease in Spain. Arch Neurol. 2002;59(6):966-970.
                32. ras J, Guerreiro R, Ribeiro M, Morgadinho A, Januario C, Dias M, et al. Analysis of Parkinson disease patients from Por-tugal for mutations in SNCA, PRKN, PINK1 and LRRK2. BMC Neurol. 2008;8:1.
                33. Dachsel JC, Mata IF, Ross OA, Taylor JP, Lincoln SJ, Hinkle KM, et al. Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. Neurosci Lett. 2006;410(2):80-84.
                34. Rawal N, Periquet M, Lohmann E, Lucking CB, Teive HA, Ambrosio G, et al. New parkin mutations and atypical phe-notypes in families with autosomal recessive parkinsonism. Neurology. 2003;60(8):1378-1381.
                35. Okatsu K, Oka T, Iguchi M, Imamura K, Kosako H, Tani N, et al. PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mi-tochondria. Nat Commun. 2012;3:1016.
                36. Tan JM, Wong ES, Lim KL.Protein misfolding and ag-gregation in Parkinson’s disease. Antioxid Redox Signal. 2009;11(9):2119-2134.
                37. Johnson BN, Berger AK, Cortese GP, Lavoie MJ. The ubi-quitin E3 ligase parkin regulates the proapoptotic function of Bax. Proc Natl Acad Sci U S A. 2012;109(16):6283-6288.
                38. Lesage S, Lohmann E, Tison F, Durif F, Durr A, Brice A. Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet. 2008;45(1):43-46.
                39. Hedrich K, Marder K, Harris J, Kann M, Lynch T, Meija-Santana H, et al. Evaluation of 50 probands with early-onset Parkinson’s disease for Parkin mutations. Neurology. 2002;58(8):1239-1246.
                40. Brooks J, Ding J, Simon-Sanchez J, Paisan-Ruiz C, Sin-gleton AB, Scholz SW. Parkin and PINK1 mutations in early-onset Parkinson’s disease: comprehensive screening in publicly available cases and control. J Med Genet. 2009;46(6):375-381.
                41. Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol. 2006;63(6):826-832.
                42. |Chung EJ, Ki CS, Lee WY, Kim IS, Kim JY. Clinical features and gene analysis in Korean patients with early-onset Parkin-son disease. Arch Neurol. 2006;63(8):1170-1174.
                43. Deng H, Le W, Shahed J, Xie W, Jankovic J. Mutation analysis of the parkin and PINK1 genes in American Cau-casian early-onset Parkinson disease families. Neurosci Lett. 2008;430(1):18-22.
                44. ============================================
                45. DOI: http://dx.doi.org/10.22490/24629448.993
                Tutorials

                Autors:

                How send article?

                Evaluator pair

                How to evaluate an article?

                Information

                Keywords

                Google Scholar profile

                Is part of
                 
                Más leídos en los últimos 30 días

                Current Issue

                Sistema OJS 3.4.0.5 - Metabiblioteca |